Aradigm Corporation - Product Pipeline Review - 2013

Logo

Naperville, IL -- (SBWire) -- 07/08/2013 --Reportstack, provider of premium market research reports announces the addition of Aradigm Corporation - Product Pipeline Review - 2013 market report to its offering
Aradigm Corporation - Product Pipeline Review - 2013

Summary

Global Market Direct's pharmaceuticals report, Aradigm Corporation - Product Pipeline Review - 2013 provides data on the Aradigm Corporation's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Aradigm Corporation's corporate website, SEC filings, investor presentations and featured press releases, both from Aradigm Corporation and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Aradigm Corporation - Brief Aradigm Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Aradigm Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Aradigm Corporation with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Aradigm Corporation's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Aradigm Corporation's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Aradigm Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Aradigm Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Aradigm Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Aradigm Corporation and identify potential opportunities in those areas.

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/116745/aradigm-corporation-product-pipeline-review-2013.html

Media Relations Contact

Web Master
http://www.reportstack.com

View this press release online at: http://rwire.com/274250